GREAT POINT PARTNERS LLC - Q3 2020 holdings

$1.11 Billion is the total value of GREAT POINT PARTNERS LLC's 34 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 40.0% .

 Value Shares↓ Weighting
SAGE SellSAGE THERAPEUTICS INC$120,204,000
+37.5%
1,966,688
-6.5%
10.81%
+54.7%
ARNA SellARENA PHARMACEUTICALS INC$74,558,000
-9.1%
996,898
-23.5%
6.71%
+2.3%
ZYME SellZYMEWORKS INC$73,033,000
-21.4%
1,567,900
-39.1%
6.57%
-11.5%
CNST SellCONSTELLATION PHARMCETICLS I$57,983,000
-44.6%
2,861,924
-17.8%
5.22%
-37.6%
TGTX SellTG THERAPEUTICS INC$42,816,000
-33.8%
1,600,000
-51.8%
3.85%
-25.5%
BHVN SellBIOHAVEN PHARMACTL HLDG CO L$28,279,000
-54.0%
435,000
-48.3%
2.54%
-48.2%
VCEL SellVERICEL CORP$27,439,000
+23.3%
1,480,787
-8.0%
2.47%
+38.7%
GKOS SellGLAUKOS CORP$22,091,000
+15.0%
446,097
-10.8%
1.99%
+29.4%
GERN SellGERON CORP$16,853,000
-49.8%
9,685,528
-37.1%
1.52%
-43.5%
PRTA SellPROTHENA CORP PLC$15,469,000
-29.0%
1,548,479
-25.7%
1.39%
-20.1%
VRAY SellVIEWRAY INC$9,295,000
+49.6%
2,655,763
-4.3%
0.84%
+68.2%
LQDA SellLIQUIDIA TECHNOLOGIES INC$5,853,000
-45.6%
1,189,607
-6.9%
0.53%
-38.7%
ABEO SellABEONA THERAPEUTICS INC$3,971,000
-81.1%
3,892,921
-46.0%
0.36%
-78.8%
MLND SellMILLENDO THERAPEUTICS INC$1,920,000
-25.3%
1,177,900
-19.4%
0.17%
-16.0%
OYST SellOYSTER PT PHARMA INC$1,480,000
-76.1%
70,121
-67.3%
0.13%
-73.2%
NLTX ExitNEOLEUKIN THERAPEUTICS INC$0-14,065
-100.0%
-0.02%
XLRN ExitACCELERON PHARMA INC$0-58,056
-100.0%
-0.44%
DNLI ExitDENALI THERAPEUTICS INC$0-280,000
-100.0%
-0.54%
ARVN ExitARVINAS INCcall$0-203,500
-100.0%
-0.55%
CTMX ExitCYTOMX THERAPEUTICS INC$0-1,448,604
-100.0%
-0.96%
AXNX ExitAXONICS MODULATION TECHNOLOG$0-459,503
-100.0%
-1.29%
PTCT ExitPTC THERAPEUTICS INC$0-330,000
-100.0%
-1.34%
MTEM ExitMOLECULAR TEMPLATES INC$0-1,345,397
-100.0%
-1.48%
NXTC ExitNEXTCURE INC$0-999,666
-100.0%
-1.71%
AKBA ExitAKEBIA THERAPEUTICS INC$0-3,510,073
-100.0%
-3.81%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2020-11-16
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
STREAMLINE HEALTH SOLUTNS, INC CMN25Q3 20192.5%
IOVANCE BIOTHERAPEUTICS, INC. CMN16Q1 202114.3%
ZOGENIX INC CMN16Q4 20198.8%
PTC THERAPEUTICS, INC. CMN16Q3 20239.9%
EXELIXIS, INC16Q1 20227.5%
SAGE THERAPEUTICS, INC CMN15Q3 202110.8%
CYTOKINETICS INC15Q3 20235.8%
ACADIA PHARMACEUTICALS, INC.14Q1 20218.8%
ACCELERON PHARMA INC CMN14Q2 20208.2%
CONNECTURE INC13Q4 201725.1%

View GREAT POINT PARTNERS LLC's complete holdings history.

Latest significant ownerships (13-D/G)
GREAT POINT PARTNERS LLC Q3 2020 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
89bio, Inc.February 14, 2023700,0001.4%
KalVista Pharmaceuticals, Inc.February 14, 20231,055,8013.1%
Avalo Therapeutics, Inc.February 13, 2023974,6397.1%
InflaRx N.V.Sold outFebruary 14, 202200.0%
ABEONA THERAPEUTICS INC.Sold outFebruary 16, 202100.0%
CONSTELLATION PHARMACEUTICALS INCFebruary 16, 20211,024,8002.2%
GERON CORPFebruary 16, 202112,754,2284.0%
Millendo Therapeutics, Inc.February 16, 2021270,0001.4%
NextCure, Inc.Sold outFebruary 16, 202100.0%
PROTHENA CORP PUBLIC LTD COFebruary 16, 2021977,6472.4%

View GREAT POINT PARTNERS LLC's complete significant-ownership history.

Latest filings
TypeFiled
SC 13G2024-04-08
13F-HR2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14
SC 13G/A2024-02-14

View GREAT POINT PARTNERS LLC's complete filings history.

Compare quarters

Export GREAT POINT PARTNERS LLC's holdings